Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Cell Count

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,045 result(s) found for: Blood Cell Count. Displaying page 1 of 103.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-004568-37 Sponsor Protocol Number: INV543 Start Date*: 2018-11-30
    Sponsor Name:Nova Laboratories Limited
    Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia
    Medical condition: Sickle Cell Anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-022812-37 Sponsor Protocol Number: ORH/PID/6265 Start Date*: 2011-06-07
    Sponsor Name:Oxford University Hospitals NHS Trust
    Full Title: A phase 2 trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002101-19 Sponsor Protocol Number: CACZ885X2206 Start Date*: 2016-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult pa...
    Medical condition: Sickle cell anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003485-39 Sponsor Protocol Number: NN7533-4470 Start Date*: 2022-07-19
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease
    Medical condition: Sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004209-15 Sponsor Protocol Number: GBT440-007 Start Date*: 2019-01-08
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-002987-24 Sponsor Protocol Number: 152CL201 Start Date*: 2007-06-25
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclopho...
    Medical condition: Relapsed Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) SK (Completed) PT (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005072-34 Sponsor Protocol Number: VIT-2763-SCD-202 Start Date*: 2021-07-26
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Phase 2a, double-blind, randomised, placebo controlled, efficacy, and safety study of multiple doses of VIT-2763 in subjects with sickle cell disease (ViSion Serenity)
    Medical condition: Sickle cell disease.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021786-78 Sponsor Protocol Number: V1_30.4.2010 Start Date*: 2010-11-11
    Sponsor Name:Medizinische Universität Wien
    Full Title: Treatment of chronic lymphocytic leukemia with the use of an antiviral compound - a proof of principle study
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002173-26 Sponsor Protocol Number: VX21-CTX001-151 Start Date*: 2021-10-05
    Sponsor Name:VERTEX PHARMACEUTICALS INCORPORATED
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease
    Medical condition: Severe Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2011-001113-14 Sponsor Protocol Number: TEM-IIG-2 Start Date*: 2011-12-20
    Sponsor Name:Fundación Hospital Clinic i Provincial
    Full Title: Pharmakokynetic and Pharmacodynamic study of Temsirolimus in Renal Cell Carcinoma Patients
    Medical condition: Renal Cell Carcinoma Patients
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000932-70 Sponsor Protocol Number: APHP200067 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS
    Full Title: Randomized prospective trial evaluating the efficacy of the antiCD38 monoclonal antibody isatuximab in the treatment of PCRA by major ABO mismatch after allogeneic hematopoietic stem cell transplan...
    Medical condition: Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002965 Aplasia pure red cell PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021165-76 Sponsor Protocol Number: LU2006 Start Date*: 2011-09-19
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: STOMP: Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial
    Medical condition: Small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-004548-35 Sponsor Protocol Number: 15081982 Start Date*: 2010-08-20
    Sponsor Name:Radboud university nijmegen medical centre
    Full Title: PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER
    Medical condition: Patients with metastatic clear cell renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016378-34 Sponsor Protocol Number: MI-CP204 Start Date*: 2010-06-30
    Sponsor Name:MedImmune LLC
    Full Title: An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
    Medical condition: Relapsed or refractory advanced B-cell malignancies: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL)...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004339-19 Sponsor Protocol Number: UTX-TGR-204 Start Date*: 2017-02-16
    Sponsor Name:TG Therapeutics
    Full Title: A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011225-14 Sponsor Protocol Number: Le.P.Re. Study Start Date*: 2009-05-22
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: A PROSPECTIVE, MULTICENTER PHASE II STUDY EVALUATING PREDICTIVE FACTORS FOR LENALIDOMIDE TREATMENT RESPONSE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
    Medical condition: Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia, [Hallek M et al, 2008]).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001674-34 Sponsor Protocol Number: AG348-C-020 Start Date*: 2022-02-17
    Sponsor Name:AGIOS PHARMACEUTICALS, INC.
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) FR (Ongoing) BE (Ongoing) DE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001058-16 Sponsor Protocol Number: NLG-LBC-07 Start Date*: 2017-02-15
    Sponsor Name:Nordic Lymphoma Group
    Full Title: A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma.
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma, including transformed low grade lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003560-31 Sponsor Protocol Number: UKM18_0021 Start Date*: 2020-01-29
    Sponsor Name:Universitätsklinikum Münster
    Full Title: A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
    Medical condition: diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001673-14 Sponsor Protocol Number: CCTL019A2205B Start Date*: 2015-10-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
    Medical condition: All patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FI (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:33:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA